AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results showed promise against rival drugs from Merck and NewAmsterdam Pharma, but AstraZeneca stock fell.

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...

Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

100 people who followed a low-carb keto diet were analyzed and high cholesterol was found to not be a marker for increased ...

A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder ...